View ValuationMedexus Pharmaceuticals 将来の成長Future 基準チェック /56Medexus Pharmaceuticals利益と収益がそれぞれ年間59.5%と14.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に30% 59.3%なると予測されています。主要情報59.5%収益成長率59.30%EPS成長率Pharmaceuticals 収益成長14.6%収益成長率14.4%将来の株主資本利益率30.03%アナリストカバレッジGood最終更新日25 May 2026今後の成長に関する最新情報お知らせ • Jan 23+ 1 more updateMedexus Pharmaceuticals Inc. Provides Earnings Guidance for the Three-Month Period Ended December 31, 2024Medexus Pharmaceuticals Inc. provided earnings guidance for the three-month period ended December 31, 2024. For the quarter, the company expects revenue between $29.5 million and $30.5 million, representing a year-over-year increase of at least 17% over $25.2 million for fiscal Third Quarter 2024, attributable in part to continuing growth in net sales of Rupall, and an approximately $2.0 million beneficial impact of customer buying patterns and related timing of orders of IXINITY relative to patient unit demand in fiscal Third Quarter 2025. Operating income between $3.5 million and $4.0 million, representing a year-over-year increase of at least 123% over $1.6 million for fiscal Third Quarter 2024. Net income between $(0.5) million and $2.0 million, compared to $(0.5) million for fiscal Third Quarter 2024. Final reported net income for fiscal Third Quarter 2025 will depend on completion of Medexus's financial closing procedures, including in respect of current and deferred income tax expense amounts.お知らせ • Jan 13Medexus Pharmaceuticals Inc. Provides Earnings Guidance for the Third Quarter of 2023Medexus Pharmaceuticals Inc. provided earnings guidance for the third quarter of 2023. For the quarter, the company expected total revenue between $28.5 million and $29.0 million.すべての更新を表示Recent updatesお知らせ • Feb 04Medexus Pharmaceuticals Inc. to Report Q3, 2026 Results on Feb 11, 2026Medexus Pharmaceuticals Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 11, 2026お知らせ • Nov 06Medexus Pharmaceuticals Inc. to Report Q2, 2026 Results on Nov 12, 2025Medexus Pharmaceuticals Inc. announced that they will report Q2, 2026 results After-Market on Nov 12, 2025お知らせ • Aug 06Medexus Pharmaceuticals Inc. to Report Q1, 2026 Results on Aug 12, 2025Medexus Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on Aug 12, 2025お知らせ • Jul 22Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 25, 2025Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 25, 2025.お知らせ • Jun 18Medexus Pharmaceuticals Inc. to Report Q4, 2025 Results on Jun 25, 2025Medexus Pharmaceuticals Inc. announced that they will report Q4, 2025 results After-Market on Jun 25, 2025お知らせ • Feb 02Medexus Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of CAD 30 million.Medexus Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of CAD 30 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: CAD 4 Discount Per Security: CAD 0.24 Security Name: Common Shares Security Type: Common Stock Securities Offered: 1,500,000 Price\Range: CAD 4 Discount Per Security: CAD 0.12 Transaction Features: Rule 144Aお知らせ • Feb 01Medexus Pharmaceuticals Inc. to Report Q3, 2025 Results on Feb 05, 2025Medexus Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Feb 05, 2025お知らせ • Jan 29Medexus Pharmaceuticals Inc. has filed a Follow-on Equity Offering.Medexus Pharmaceuticals Inc. has filed a Follow-on Equity Offering. Security Name: Common Shares Security Type: Common Stock Transaction Features: Rule 144Aお知らせ • Jan 23+ 1 more updateMedexus Pharmaceuticals Inc. Provides Earnings Guidance for the Three-Month Period Ended December 31, 2024Medexus Pharmaceuticals Inc. provided earnings guidance for the three-month period ended December 31, 2024. For the quarter, the company expects revenue between $29.5 million and $30.5 million, representing a year-over-year increase of at least 17% over $25.2 million for fiscal Third Quarter 2024, attributable in part to continuing growth in net sales of Rupall, and an approximately $2.0 million beneficial impact of customer buying patterns and related timing of orders of IXINITY relative to patient unit demand in fiscal Third Quarter 2025. Operating income between $3.5 million and $4.0 million, representing a year-over-year increase of at least 123% over $1.6 million for fiscal Third Quarter 2024. Net income between $(0.5) million and $2.0 million, compared to $(0.5) million for fiscal Third Quarter 2024. Final reported net income for fiscal Third Quarter 2025 will depend on completion of Medexus's financial closing procedures, including in respect of current and deferred income tax expense amounts.お知らせ • Nov 21Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in CanadaEarlier in November 2024, Medexus Pharmaceuticals successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to publicly funded drug programs and patients in Canada. The pCPA is an independent organization whose membership includes the provincial, territorial, and federal governments. Reaching this important milestone on November 4, 2024 was the result of a collaborative negotiation process with pCPA,¹ and followed publication of final recommendations on reimbursement from Québec's L'Institut National d'Excellence en Santé et en Services Sociaux on March 6, 2024 and from Canada's Drug Agency (formerly CADTH) on March 18, 2024, based on Medexus's July 2023 submissions to those agencies. The next step in the public reimbursement process will be for participating government organizations to make their respective final decisions on public reimbursement for their regions. Medexus is committed to continuing to work with participating provincial, territorial, and federal government organizations to make Trecondyv® available as soon as possible through public drug plans for the patients who need it.お知らせ • Oct 30Medexus Pharmaceuticals Inc. to Report Q2, 2025 Results on Nov 07, 2024Medexus Pharmaceuticals Inc. announced that they will report Q2, 2025 results After-Market on Nov 07, 2024お知らせ • Jul 31Medexus Pharmaceuticals Inc. to Report Q1, 2025 Results on Aug 07, 2024Medexus Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on Aug 07, 2024お知らせ • Jul 16Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 19, 2024Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 19, 2024.お知らせ • Jun 19Medexus Pharmaceuticals Inc. to Report Q4, 2024 Results on Jun 25, 2024Medexus Pharmaceuticals Inc. announced that they will report Q4, 2024 results After-Market on Jun 25, 2024お知らせ • Jun 08Medexus Pharmaceuticals Inc. Announces FDA Accepts for Review Treosulfan NDAMedexus Pharmaceuticals was informed by medac that the US Food and Drug Administration has accepted for review medac's April 2024 resubmission of the New Drug Application for treosulfan. Medexus expects that the FDA will complete its review of the treosulfan NDA and issue a decision by October 30, 2024. The treosulfan NDA seeks approval of treosulfan in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients. medac's resubmission provided additional information that had previously been requested by the FDA relating to the pivotal phase 3 clinical trial of treosulfan conducted by medac. Medexus successfully launched treosulfan in Canada under the brand name Trecondyv® in September 2021, and since launch has gained valuable experience commercializing the product in that market. This success in Canada supports Medexus's optimism regarding treosulfan's potential positive impact in the US market if and when approved. Under the terms of a September 2023 amendment to Medexus's February 2021 exclusive license agreement relating to commercialization of treosulfan in the United States, Medexus and medac now have a specified negotiation period to agree to a further amendment with respect to any adjustments to the value of unpaid regulatory and sales-based milestone payments that the parties may agree are appropriate in the prevailing circumstances. Medexus will have no obligation to make any milestone payments before the effective date of any such further amendment to the US treosulfan agreement.お知らせ • Jan 31Medexus Pharmaceuticals Inc. to Report Q3, 2024 Results on Feb 07, 2024Medexus Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Feb 07, 2024お知らせ • Jan 09Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N InfectionsMedexus Pharmaceuticals announced that Health Canada recently accepted for review Medexus's new drug submission, or NDS, for terbinafine hydrochloride nail lacquer to treat fungal nail infections. Medexus's NDS for topical terbinafine seeks Health Canada approval for a distinctive once-a week treatment regimen. If and when approved, the product will enter the Canadian topical fungicides market that is estimated to be CAD 88 million on an annual basis.お知らせ • Nov 02Medexus Pharmaceuticals Inc. to Report Q2, 2024 Results on Nov 08, 2023Medexus Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Nov 08, 2023お知らせ • Oct 07Medexus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 10.000205 million.Medexus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 10.000205 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 3,389,900 Price\Range: CAD 2.95 Discount Per Security: CAD 0.177お知らせ • Aug 18Medexus Pharmaceuticals Announces the Presentation of Data from Phase 3/4 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of IXINITYMedexus Pharmaceuticals Inc. announced the presentation of data from a Phase 3/4 study that evaluated the pharmacokinetics (PK), safety, and efficacy of IXINITY, an intravenous recombinant factor IX therapeutic, as a prophylactic treatment in previously treated pediatric patients under 12 years of age with severe or moderately severe hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood. In a poster presentation at the National Hemophilia Foundation (NHF) Bleeding Disorders Conference 2023 in National Harbor, Maryland, researchers reported that prophylaxis with IXINITY was associated with low annualized bleeding rates (ABRs), effective control of bleeding episodes, consistent PK, and a consistent safety profile. IXINITY is currently approved for use in patients 12 years of age or older with hemophilia B.お知らせ • Aug 03Medexus Pharmaceuticals Inc. to Report Q1, 2024 Results on Aug 09, 2023Medexus Pharmaceuticals Inc. announced that they will report Q1, 2024 results After-Market on Aug 09, 2023お知らせ • Jul 15Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 21, 2023Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 21, 2023.お知らせ • Jun 15Medexus Pharmaceuticals Inc. to Report Q4, 2023 Results on Jun 21, 2023Medexus Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Jun 21, 2023お知らせ • Jun 14Medexus Pharmaceuticals Presents Positive New Data on Treosulfan That Researchers At Toronto's Princess Margaret Hospital Recently Presented At Mds 2023Medexus Pharmaceuticals Inc. announced to highlight positive new data on treosulfan that researchers at Toronto's Princess Margaret Hospital (PMH) recently presented at MDS 2023, the 17th annual International Congress on Myelodysplastic Syndromes, held in Marseille, France. The study, a retrospective analysis of patient outcomes, further confirms Medexus's optimism regarding treosulfan's potential positive impact in both Canada and the United States. The MDS 2023 presentation is substantially consistent with the previously published final study results and analysis of the pivotal phase 3 clinical trial of treosulfan, which Medexus announced in June 2022. Among other things, that earlier study demonstrated clinically relevant superiority of treosulfan over a reduced-intensity conditioning busulfan regimen with regard to event-free survival, that study's primary endpoint. Treosulfan is part of a preparative regimen for allogeneic hematopoietic stem cell transplantation, to be used in combination with fludarabine, used in treating eligible patients with acute myeloid leukemia and myelodysplastic syndromes. Final study results and analysis of The pivotal phase 3 clinical trial of Treosulfan conducted by medac GmbH, which was published in the American Journal of Hematology, concluded that the study demonstrates clinically relevant superiority of treos sulfan over a widely applied "reduced-intensity conditioning" busulfan regimen with regard To its primary endpoint, event-free survival. The publication also includes favorable conclusions on two key secondary endpoints, finding that overall survival with treosulfan was superior compared to busulfan and that non-relapse mortality for patients in the treosulfan arm was lower than for patients in the busulfan arm. During the phase 3 clinical trial of treOSulfan, treatment emergent adverse events (TEAEs) were reported by 92.6% of patients in the treosulf an treatment group.お知らせ • Feb 07Medexus Pharmaceuticals Inc. Announces Board AppointmentsMedexus Pharmaceuticals welcome Harmony P. Garges MD MPH, Chief Medical Officer of ViiV Healthcare, and Menassie Taddese MBA, former executive at Pfizer and Viatris, to the Medexus board of directors. Dr Garges and Mr Taddese were elected to fill two newly created directorships with effect as of February 6, 2023 and will initially serve until the next annual meeting of Medexus shareholders. Harmony P. Garges MD MPH brings 18 years of multinational pharmaceutical leadership experience in the United States and the UK to the Medexus board. Dr Garges has served as Chief Medical Officer of ViiV Healthcare since August 2019. In this role, Dr Garges is accountable for all aspects of human safety and medical governance and for the global medical affairs strategy and execution for the company. Dr Garges joined ViiV Healthcare in 2016 after spending over a decade at GSK in various leadership roles across R&D, pharmacovigilance, and medical affairs. During her career, Dr Garges has provided medical leadership for over a dozen new drug applications and new product launches. Menassie Taddese MBA is a seasoned veteran of the biopharmaceutical industry with wide ranging experience ingeneral management, finance, business transformation, partnership creation, and overall leadership. He bringsover 26 years of experience leading large commercial and cross-functional organizations across the globe to theMedexus board.お知らせ • Feb 01Medexus Pharmaceuticals Inc. to Report Q3, 2023 Results on Feb 08, 2023Medexus Pharmaceuticals Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Feb 08, 2023お知らせ • Jan 13Medexus Pharmaceuticals Inc. Provides Earnings Guidance for the Third Quarter of 2023Medexus Pharmaceuticals Inc. provided earnings guidance for the third quarter of 2023. For the quarter, the company expected total revenue between $28.5 million and $29.0 million.お知らせ • Dec 20Medexus Pharmaceuticals Inc. Enters into Exclusive License Agreement with EthypharmMedexus Pharmaceuticals Inc. announce it has entered into an exclusive license agreement with Ethypharm ("Ethypharm") to register and commercialize Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL ("TH") in the United States. TH is indicated for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases, including: rheumatoid arthritis, juvenile idiopathic arthritis (JIA), osteoarthritis and post-traumatic arthritis, synovitis, tendinitis, bursitis and epicondylitis. It is the longest-acting corticosteroid for intra articular injection, often lasting twice as long as competitive products. The companies have agreed to a small upfront fee, which will be funded by Medexus with available liquidity, along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones. Medexus will also pay a double-digit royalty to Ethypharm on net sales of TH in the United States. TH has the potential to become the standard of care by offering a longer duration of action along with fewer injections (and by extension, fewer hospital visits and eneral anesthetics), as well as a safer and more cost-effective solution than competitive products. The Company expects to file for FDA approval of TH within 12-24 months.お知らせ • Nov 17Medexus Pharmaceuticals Inc. Reaches 50% Enrollment Target in Its Phase 4 Clinical Trial Investigating Ixinity® as Prophylactic Treatment for Pediatric Patients Under 12 Years of AgeMedexus Pharmaceuticals Inc. announced it has reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX. IXINITY is an FDA approved intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B. On February 28, 2020, Medexus announced the acquisition of the worldwide rights to the commercial hematology asset, IXINITY®, from Aptevo Therapeutics Inc. In January 2020, Aptevo had already commenced dosing patients in a Phase 4 clinical trial to evaluate the safety and efficacy of IXINITY® in previously treated patients under 12 years of age with hemophilia B. Once completed, this study may support a significant expansion of the indicated patient population for IXINITY®. According to the World Federation of Hemophilia `Report on the Annual Global Survey 2017,' approximately 1 in 3 patients treated for hemophilia B in the U.S. are 12 years of age or younger. Most importantly, look forward to providing this important, additional therapy option to the pediatric population. Previously reported and pooled data from Phase 3 clinical trials demonstrated IXINITY® to be safe and well tolerated in preventing and controlling bleeding episodes in previously treated children under the age of 12 with hemophilia B. Remain determined to advance IXINITY® Phase 4 pediatric clinical trial and look forward to providing further updates as achieve key milestones. Medexus intends to also pursue out-license partners for IXINITY® in markets outside of Canada and the United States. The company will provide further updates as they develop.お知らせ • Nov 10Medexus Pharmaceuticals Inc. to Report Q2, 2021 Results on Nov 16, 2020Medexus Pharmaceuticals Inc. announced that they will report Q2, 2021 results at 9:00 AM, Eastern Standard Time on Nov 16, 2020お知らせ • Sep 26Medexus Pharmaceuticals Inc. Appoints Michael Pine as Senior Vice President of Business Development and StrategyMedexus Pharmaceuticals Inc. announced the appointment of Michael Pine as Senior Vice President of Business Development and Strategy, effective September 21, 2020. Mr. Pine’s responsibilities include developing Medexus’ product portfolio in both the U.S. and Canada. Mr. Pine is an experienced pharmaceutical industry executive and business leader with a diverse background in both large and small pharmaceutical companies that includes functions in: business development & licensing, M&A, investment banking, business strategy, product marketing, US managed markets, and operations. Most recently, Mr. Pine served as SVP, Business Development & Licensing at Lupin Pharmaceuticals, where he led Lupin's efforts to expand their over $2 billion revenue base further into branded and specialty products with a focus on the North American markets. Prior to that role, Mr. Pine was the VP, Head of Corporate Development & Licensing at Aralez Pharmaceuticals. Mr. Pine also served in a variety of senior roles at companies such as Novartis, Kos Pharmaceuticals, Organon Biosciences, Pfizer, and JP Morgan Chase. Mr. Pine has a BS in Consumer Economics from Cornell University and an MBA from Columbia Business School.お知らせ • Aug 06Medexus Pharmaceuticals Inc. to Report Q1, 2021 Results on Aug 11, 2020Medexus Pharmaceuticals Inc. announced that they will report Q1, 2021 results on Aug 11, 2020お知らせ • Jun 18Medexus Pharmaceuticals Inc. to Report Fiscal Year 2020 Results on Jun 22, 2020Medexus Pharmaceuticals Inc. announced that they will report fiscal year 2020 results at 5:00 PM, Eastern Standard Time on Jun 22, 2020業績と収益の成長予測OTCPK:MEDX.F - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202916239N/A4433/31/202814024N/A2943/31/20271148N/A1663/31/20261000N/A19612/31/20259901017N/A9/30/202510401316N/A6/30/202510611420N/A3/31/202510822124N/A12/31/202411042023N/A9/30/202410521922N/A6/30/202410912223N/A3/31/202411301819N/A12/31/202311662121N/A9/30/202311951313N/A6/30/2023117367N/A3/31/20231081-2-1N/A12/31/2022100-11-3-2N/A9/30/202292-11-3-1N/A6/30/202282202N/A3/31/202277-3-9-1N/A12/31/202174-8-17-1N/A9/30/202177-20-18-1N/A6/30/202177-31-21-5N/A3/31/202180-28-65N/A12/31/202079-19-10N/A9/30/202069-911N/A6/30/202064-711N/A3/31/202056-5-3-2N/A12/31/201947-4-10N/A9/30/201945-3N/A0N/A6/30/201936-6N/A-1N/A3/31/201925-5N/A-1N/A12/31/201817-5N/A-2N/A9/30/20189-5N/A-1N/A6/30/20188-2N/A-2N/A3/31/20188-3N/A-3N/A12/31/20178-3N/A-3N/A9/30/20177-3N/A-4N/A6/30/20176-3N/A-4N/A3/31/20175-1N/A-1N/A12/31/201641N/A1N/A9/30/201631N/A1N/A6/30/201631N/A1N/A3/31/20163-2N/A-1N/A12/31/20153-4N/A-3N/A9/30/20152-4N/A-3N/A6/30/20152-5N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MEDX.Fは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。収益対市場: MEDX.F今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: MEDX.F今後 3 年以内に収益を上げることが予想されます。収益対市場: MEDX.Fの収益 ( 14.4% ) US市場 ( 11.9% ) よりも速いペースで成長すると予測されています。高い収益成長: MEDX.Fの収益 ( 14.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MEDX.Fの 自己資本利益率 は、3年後には高くなると予測されています ( 30 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 11:36終値2026/05/29 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medexus Pharmaceuticals Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Scott HenryAlliance Global PartnersTania Armstrong-WhitworthATB Cormark Historical (Cormark Securities)David MartinBloom Burton & Co.7 その他のアナリストを表示
お知らせ • Jan 23+ 1 more updateMedexus Pharmaceuticals Inc. Provides Earnings Guidance for the Three-Month Period Ended December 31, 2024Medexus Pharmaceuticals Inc. provided earnings guidance for the three-month period ended December 31, 2024. For the quarter, the company expects revenue between $29.5 million and $30.5 million, representing a year-over-year increase of at least 17% over $25.2 million for fiscal Third Quarter 2024, attributable in part to continuing growth in net sales of Rupall, and an approximately $2.0 million beneficial impact of customer buying patterns and related timing of orders of IXINITY relative to patient unit demand in fiscal Third Quarter 2025. Operating income between $3.5 million and $4.0 million, representing a year-over-year increase of at least 123% over $1.6 million for fiscal Third Quarter 2024. Net income between $(0.5) million and $2.0 million, compared to $(0.5) million for fiscal Third Quarter 2024. Final reported net income for fiscal Third Quarter 2025 will depend on completion of Medexus's financial closing procedures, including in respect of current and deferred income tax expense amounts.
お知らせ • Jan 13Medexus Pharmaceuticals Inc. Provides Earnings Guidance for the Third Quarter of 2023Medexus Pharmaceuticals Inc. provided earnings guidance for the third quarter of 2023. For the quarter, the company expected total revenue between $28.5 million and $29.0 million.
お知らせ • Feb 04Medexus Pharmaceuticals Inc. to Report Q3, 2026 Results on Feb 11, 2026Medexus Pharmaceuticals Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 11, 2026
お知らせ • Nov 06Medexus Pharmaceuticals Inc. to Report Q2, 2026 Results on Nov 12, 2025Medexus Pharmaceuticals Inc. announced that they will report Q2, 2026 results After-Market on Nov 12, 2025
お知らせ • Aug 06Medexus Pharmaceuticals Inc. to Report Q1, 2026 Results on Aug 12, 2025Medexus Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on Aug 12, 2025
お知らせ • Jul 22Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 25, 2025Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 25, 2025.
お知らせ • Jun 18Medexus Pharmaceuticals Inc. to Report Q4, 2025 Results on Jun 25, 2025Medexus Pharmaceuticals Inc. announced that they will report Q4, 2025 results After-Market on Jun 25, 2025
お知らせ • Feb 02Medexus Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of CAD 30 million.Medexus Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of CAD 30 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: CAD 4 Discount Per Security: CAD 0.24 Security Name: Common Shares Security Type: Common Stock Securities Offered: 1,500,000 Price\Range: CAD 4 Discount Per Security: CAD 0.12 Transaction Features: Rule 144A
お知らせ • Feb 01Medexus Pharmaceuticals Inc. to Report Q3, 2025 Results on Feb 05, 2025Medexus Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Feb 05, 2025
お知らせ • Jan 29Medexus Pharmaceuticals Inc. has filed a Follow-on Equity Offering.Medexus Pharmaceuticals Inc. has filed a Follow-on Equity Offering. Security Name: Common Shares Security Type: Common Stock Transaction Features: Rule 144A
お知らせ • Jan 23+ 1 more updateMedexus Pharmaceuticals Inc. Provides Earnings Guidance for the Three-Month Period Ended December 31, 2024Medexus Pharmaceuticals Inc. provided earnings guidance for the three-month period ended December 31, 2024. For the quarter, the company expects revenue between $29.5 million and $30.5 million, representing a year-over-year increase of at least 17% over $25.2 million for fiscal Third Quarter 2024, attributable in part to continuing growth in net sales of Rupall, and an approximately $2.0 million beneficial impact of customer buying patterns and related timing of orders of IXINITY relative to patient unit demand in fiscal Third Quarter 2025. Operating income between $3.5 million and $4.0 million, representing a year-over-year increase of at least 123% over $1.6 million for fiscal Third Quarter 2024. Net income between $(0.5) million and $2.0 million, compared to $(0.5) million for fiscal Third Quarter 2024. Final reported net income for fiscal Third Quarter 2025 will depend on completion of Medexus's financial closing procedures, including in respect of current and deferred income tax expense amounts.
お知らせ • Nov 21Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in CanadaEarlier in November 2024, Medexus Pharmaceuticals successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to publicly funded drug programs and patients in Canada. The pCPA is an independent organization whose membership includes the provincial, territorial, and federal governments. Reaching this important milestone on November 4, 2024 was the result of a collaborative negotiation process with pCPA,¹ and followed publication of final recommendations on reimbursement from Québec's L'Institut National d'Excellence en Santé et en Services Sociaux on March 6, 2024 and from Canada's Drug Agency (formerly CADTH) on March 18, 2024, based on Medexus's July 2023 submissions to those agencies. The next step in the public reimbursement process will be for participating government organizations to make their respective final decisions on public reimbursement for their regions. Medexus is committed to continuing to work with participating provincial, territorial, and federal government organizations to make Trecondyv® available as soon as possible through public drug plans for the patients who need it.
お知らせ • Oct 30Medexus Pharmaceuticals Inc. to Report Q2, 2025 Results on Nov 07, 2024Medexus Pharmaceuticals Inc. announced that they will report Q2, 2025 results After-Market on Nov 07, 2024
お知らせ • Jul 31Medexus Pharmaceuticals Inc. to Report Q1, 2025 Results on Aug 07, 2024Medexus Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on Aug 07, 2024
お知らせ • Jul 16Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 19, 2024Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 19, 2024.
お知らせ • Jun 19Medexus Pharmaceuticals Inc. to Report Q4, 2024 Results on Jun 25, 2024Medexus Pharmaceuticals Inc. announced that they will report Q4, 2024 results After-Market on Jun 25, 2024
お知らせ • Jun 08Medexus Pharmaceuticals Inc. Announces FDA Accepts for Review Treosulfan NDAMedexus Pharmaceuticals was informed by medac that the US Food and Drug Administration has accepted for review medac's April 2024 resubmission of the New Drug Application for treosulfan. Medexus expects that the FDA will complete its review of the treosulfan NDA and issue a decision by October 30, 2024. The treosulfan NDA seeks approval of treosulfan in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients. medac's resubmission provided additional information that had previously been requested by the FDA relating to the pivotal phase 3 clinical trial of treosulfan conducted by medac. Medexus successfully launched treosulfan in Canada under the brand name Trecondyv® in September 2021, and since launch has gained valuable experience commercializing the product in that market. This success in Canada supports Medexus's optimism regarding treosulfan's potential positive impact in the US market if and when approved. Under the terms of a September 2023 amendment to Medexus's February 2021 exclusive license agreement relating to commercialization of treosulfan in the United States, Medexus and medac now have a specified negotiation period to agree to a further amendment with respect to any adjustments to the value of unpaid regulatory and sales-based milestone payments that the parties may agree are appropriate in the prevailing circumstances. Medexus will have no obligation to make any milestone payments before the effective date of any such further amendment to the US treosulfan agreement.
お知らせ • Jan 31Medexus Pharmaceuticals Inc. to Report Q3, 2024 Results on Feb 07, 2024Medexus Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Feb 07, 2024
お知らせ • Jan 09Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N InfectionsMedexus Pharmaceuticals announced that Health Canada recently accepted for review Medexus's new drug submission, or NDS, for terbinafine hydrochloride nail lacquer to treat fungal nail infections. Medexus's NDS for topical terbinafine seeks Health Canada approval for a distinctive once-a week treatment regimen. If and when approved, the product will enter the Canadian topical fungicides market that is estimated to be CAD 88 million on an annual basis.
お知らせ • Nov 02Medexus Pharmaceuticals Inc. to Report Q2, 2024 Results on Nov 08, 2023Medexus Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Nov 08, 2023
お知らせ • Oct 07Medexus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 10.000205 million.Medexus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 10.000205 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 3,389,900 Price\Range: CAD 2.95 Discount Per Security: CAD 0.177
お知らせ • Aug 18Medexus Pharmaceuticals Announces the Presentation of Data from Phase 3/4 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of IXINITYMedexus Pharmaceuticals Inc. announced the presentation of data from a Phase 3/4 study that evaluated the pharmacokinetics (PK), safety, and efficacy of IXINITY, an intravenous recombinant factor IX therapeutic, as a prophylactic treatment in previously treated pediatric patients under 12 years of age with severe or moderately severe hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood. In a poster presentation at the National Hemophilia Foundation (NHF) Bleeding Disorders Conference 2023 in National Harbor, Maryland, researchers reported that prophylaxis with IXINITY was associated with low annualized bleeding rates (ABRs), effective control of bleeding episodes, consistent PK, and a consistent safety profile. IXINITY is currently approved for use in patients 12 years of age or older with hemophilia B.
お知らせ • Aug 03Medexus Pharmaceuticals Inc. to Report Q1, 2024 Results on Aug 09, 2023Medexus Pharmaceuticals Inc. announced that they will report Q1, 2024 results After-Market on Aug 09, 2023
お知らせ • Jul 15Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 21, 2023Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 21, 2023.
お知らせ • Jun 15Medexus Pharmaceuticals Inc. to Report Q4, 2023 Results on Jun 21, 2023Medexus Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Jun 21, 2023
お知らせ • Jun 14Medexus Pharmaceuticals Presents Positive New Data on Treosulfan That Researchers At Toronto's Princess Margaret Hospital Recently Presented At Mds 2023Medexus Pharmaceuticals Inc. announced to highlight positive new data on treosulfan that researchers at Toronto's Princess Margaret Hospital (PMH) recently presented at MDS 2023, the 17th annual International Congress on Myelodysplastic Syndromes, held in Marseille, France. The study, a retrospective analysis of patient outcomes, further confirms Medexus's optimism regarding treosulfan's potential positive impact in both Canada and the United States. The MDS 2023 presentation is substantially consistent with the previously published final study results and analysis of the pivotal phase 3 clinical trial of treosulfan, which Medexus announced in June 2022. Among other things, that earlier study demonstrated clinically relevant superiority of treosulfan over a reduced-intensity conditioning busulfan regimen with regard to event-free survival, that study's primary endpoint. Treosulfan is part of a preparative regimen for allogeneic hematopoietic stem cell transplantation, to be used in combination with fludarabine, used in treating eligible patients with acute myeloid leukemia and myelodysplastic syndromes. Final study results and analysis of The pivotal phase 3 clinical trial of Treosulfan conducted by medac GmbH, which was published in the American Journal of Hematology, concluded that the study demonstrates clinically relevant superiority of treos sulfan over a widely applied "reduced-intensity conditioning" busulfan regimen with regard To its primary endpoint, event-free survival. The publication also includes favorable conclusions on two key secondary endpoints, finding that overall survival with treosulfan was superior compared to busulfan and that non-relapse mortality for patients in the treosulfan arm was lower than for patients in the busulfan arm. During the phase 3 clinical trial of treOSulfan, treatment emergent adverse events (TEAEs) were reported by 92.6% of patients in the treosulf an treatment group.
お知らせ • Feb 07Medexus Pharmaceuticals Inc. Announces Board AppointmentsMedexus Pharmaceuticals welcome Harmony P. Garges MD MPH, Chief Medical Officer of ViiV Healthcare, and Menassie Taddese MBA, former executive at Pfizer and Viatris, to the Medexus board of directors. Dr Garges and Mr Taddese were elected to fill two newly created directorships with effect as of February 6, 2023 and will initially serve until the next annual meeting of Medexus shareholders. Harmony P. Garges MD MPH brings 18 years of multinational pharmaceutical leadership experience in the United States and the UK to the Medexus board. Dr Garges has served as Chief Medical Officer of ViiV Healthcare since August 2019. In this role, Dr Garges is accountable for all aspects of human safety and medical governance and for the global medical affairs strategy and execution for the company. Dr Garges joined ViiV Healthcare in 2016 after spending over a decade at GSK in various leadership roles across R&D, pharmacovigilance, and medical affairs. During her career, Dr Garges has provided medical leadership for over a dozen new drug applications and new product launches. Menassie Taddese MBA is a seasoned veteran of the biopharmaceutical industry with wide ranging experience ingeneral management, finance, business transformation, partnership creation, and overall leadership. He bringsover 26 years of experience leading large commercial and cross-functional organizations across the globe to theMedexus board.
お知らせ • Feb 01Medexus Pharmaceuticals Inc. to Report Q3, 2023 Results on Feb 08, 2023Medexus Pharmaceuticals Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Feb 08, 2023
お知らせ • Jan 13Medexus Pharmaceuticals Inc. Provides Earnings Guidance for the Third Quarter of 2023Medexus Pharmaceuticals Inc. provided earnings guidance for the third quarter of 2023. For the quarter, the company expected total revenue between $28.5 million and $29.0 million.
お知らせ • Dec 20Medexus Pharmaceuticals Inc. Enters into Exclusive License Agreement with EthypharmMedexus Pharmaceuticals Inc. announce it has entered into an exclusive license agreement with Ethypharm ("Ethypharm") to register and commercialize Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL ("TH") in the United States. TH is indicated for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases, including: rheumatoid arthritis, juvenile idiopathic arthritis (JIA), osteoarthritis and post-traumatic arthritis, synovitis, tendinitis, bursitis and epicondylitis. It is the longest-acting corticosteroid for intra articular injection, often lasting twice as long as competitive products. The companies have agreed to a small upfront fee, which will be funded by Medexus with available liquidity, along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones. Medexus will also pay a double-digit royalty to Ethypharm on net sales of TH in the United States. TH has the potential to become the standard of care by offering a longer duration of action along with fewer injections (and by extension, fewer hospital visits and eneral anesthetics), as well as a safer and more cost-effective solution than competitive products. The Company expects to file for FDA approval of TH within 12-24 months.
お知らせ • Nov 17Medexus Pharmaceuticals Inc. Reaches 50% Enrollment Target in Its Phase 4 Clinical Trial Investigating Ixinity® as Prophylactic Treatment for Pediatric Patients Under 12 Years of AgeMedexus Pharmaceuticals Inc. announced it has reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX. IXINITY is an FDA approved intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B. On February 28, 2020, Medexus announced the acquisition of the worldwide rights to the commercial hematology asset, IXINITY®, from Aptevo Therapeutics Inc. In January 2020, Aptevo had already commenced dosing patients in a Phase 4 clinical trial to evaluate the safety and efficacy of IXINITY® in previously treated patients under 12 years of age with hemophilia B. Once completed, this study may support a significant expansion of the indicated patient population for IXINITY®. According to the World Federation of Hemophilia `Report on the Annual Global Survey 2017,' approximately 1 in 3 patients treated for hemophilia B in the U.S. are 12 years of age or younger. Most importantly, look forward to providing this important, additional therapy option to the pediatric population. Previously reported and pooled data from Phase 3 clinical trials demonstrated IXINITY® to be safe and well tolerated in preventing and controlling bleeding episodes in previously treated children under the age of 12 with hemophilia B. Remain determined to advance IXINITY® Phase 4 pediatric clinical trial and look forward to providing further updates as achieve key milestones. Medexus intends to also pursue out-license partners for IXINITY® in markets outside of Canada and the United States. The company will provide further updates as they develop.
お知らせ • Nov 10Medexus Pharmaceuticals Inc. to Report Q2, 2021 Results on Nov 16, 2020Medexus Pharmaceuticals Inc. announced that they will report Q2, 2021 results at 9:00 AM, Eastern Standard Time on Nov 16, 2020
お知らせ • Sep 26Medexus Pharmaceuticals Inc. Appoints Michael Pine as Senior Vice President of Business Development and StrategyMedexus Pharmaceuticals Inc. announced the appointment of Michael Pine as Senior Vice President of Business Development and Strategy, effective September 21, 2020. Mr. Pine’s responsibilities include developing Medexus’ product portfolio in both the U.S. and Canada. Mr. Pine is an experienced pharmaceutical industry executive and business leader with a diverse background in both large and small pharmaceutical companies that includes functions in: business development & licensing, M&A, investment banking, business strategy, product marketing, US managed markets, and operations. Most recently, Mr. Pine served as SVP, Business Development & Licensing at Lupin Pharmaceuticals, where he led Lupin's efforts to expand their over $2 billion revenue base further into branded and specialty products with a focus on the North American markets. Prior to that role, Mr. Pine was the VP, Head of Corporate Development & Licensing at Aralez Pharmaceuticals. Mr. Pine also served in a variety of senior roles at companies such as Novartis, Kos Pharmaceuticals, Organon Biosciences, Pfizer, and JP Morgan Chase. Mr. Pine has a BS in Consumer Economics from Cornell University and an MBA from Columbia Business School.
お知らせ • Aug 06Medexus Pharmaceuticals Inc. to Report Q1, 2021 Results on Aug 11, 2020Medexus Pharmaceuticals Inc. announced that they will report Q1, 2021 results on Aug 11, 2020
お知らせ • Jun 18Medexus Pharmaceuticals Inc. to Report Fiscal Year 2020 Results on Jun 22, 2020Medexus Pharmaceuticals Inc. announced that they will report fiscal year 2020 results at 5:00 PM, Eastern Standard Time on Jun 22, 2020